News

Articles

Bayer will own the rights to AskBio’s AAV-based gene therapy platform, its intellectual property portfolio, and an established CDMO.

Bayer to Acquire AskBio for up to $4 Billion

Gilead’s antiviral drug Veklury is the first approved treatment in the US for COVID-19.

FDA Approves Remdesivir for Hospitalized Patients

200 employees will be hired by the end of 2020, with 300 more planning to be hired by 2023. 

Roche Canada to Invest $500 Million and Create 500 New Jobs at its Canadian Global Pharma Technical Operations Site

Regeneron will distribute Inmazeb treatment doses over the course of six years to BARDA.

FDA Approves Regeneron’s Inmazeb as the First Treatment for Ebola

Roche will use Dyno’s CapsidMap platform to develop next-generation adeno-associated virus vectors for gene therapies for central nervous system diseases and liver-directed therapies. 

Roche and Dyno Therapeutics to Enter into $1.8 Billion Collaboration 

The companies are entering into an agreement for the late-stage development and large-scale manufacturing of AZD7442, AstraZeneca’s investigational product for treatment and prevention of COVID-19.

HHS, DoD, AstraZeneca Enter into $486-Million Agreement for COVID-19 Investigational Product

Through the acquisition, Bristol Myers Squibb will gain access to MyoKardia’s mavacamten, a cardiovascular drug for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease.



Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi Completes $3.68-Billion Acquisition of Principia Biopharma

Samsung will offer large-scale commercial manufacturing for drug substance and drug products to support AstraZeneca’s biologics therapeutics capabilities in the Asia-Pacific region.

AstraZeneca and Samsung Biologics to Enter into Long-Term Supply Agreement for Up to $545.6 Million

Valneva will supply the UK government with an initial 60 million doses of the vaccine in the second half of 2021, if successful, and will provide more doses thereafter. 

Valneva Enters into $1.6-Billion Partnership with UK Government for COVID-19 Vaccine

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The White House issued an executive order Sunday, Sept. 13, 2020 implementing a policy to link payments for medicines provided through Medicare to prices charged in other industrial countries. 

Trump Escalates Drug Pricing War

The acquisition will give Gilead access to an anti-cancer antibody drug conjugate in clinical development for treating breast and bladder cancers. 

Gilead to Acquire Immunomedics for $21 Billion

In an opinion article, FDA leaders commit to applying “the best science” to approval decisions.

Career FDA Leaders Say Science Is Agency’s Guide

As public confidence in the drug development process waivers, leading vaccine developers promise to adhere to scientific and regulatory principles.

Vaccine Developers Pledge to Stand with Science

The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.

Nestlé Health Science to Acquire Aimmune Therapeutics for $2.6 Billion

The transaction will give Ionis access to Akcea's pipeline and commercial products, as well as its cash on hand of approximately $390 million.

Ionis to Acquire Akcea Common Stock for $500 Million

FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data. 

FDA Issues EUA for COVID-19 Convalescent Plasma 

BioMarin received the complete response letter for valoctocogene roxaparvovec, its gene therapy intended for treating severe hemophilia A.

FDA Issues Complete Response Letter to BioMarin for Hemophilia A Gene Therapy

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

A new FDA guidance provides answers to such questions about when the agency will seek to visit a site during the COVID-19 pandemic and how it will respond when a needed inspection cannot be conducted safely.

FDA May Delay Approval of Drugs Where Necessary Inspection Is Not Feasible

Bristol Myers Squibb will handle the development and commercialization of DF6002 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding, and manufacturing.

Top News